EZH2 and prostate carcinoma: Indeed, mice carrying Treg-specific Ezh2 deficiency showed a reduced growth of different types of tumors (e.g., CRC, melanoma, prostate cancer) in association with the reprograming of tumor-infiltrating Tregs in anti-tumor effector cells (e.g., IL-2, IFNγ, and TNF) [116].